Diabetes
ISIS 113715 Improves Glucose Control in Patients With Type 2 Diabetes
Published in Obesity and Diabetes Week, July 11th, 2005
The second-generation antisense drug did not cause any hypoglycemia (low blood sugar) and was well-tolerated. The data reported were from an interim analysis of a randomized, double-blind, placebo-controlled Phase 2 study in diabetic patients. Data were announced in an oral presentation by Lise Kjems, M.D., Ph.D., Executive Director, Metabolic Drug Development of Isis Pharmaceuticals, at the American Diabetes Association's (ADA) 65th Scientific Sessions in San Diego.
"The results we have reported for ISIS 113715 are encouraging. After just 6...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathogenesis
Insulin signaling in the central nervous system reviewed - Insulin Resistance
iNOS plays role in impaired insulin signaling in liver of obese mice - Obesity and Diabetes
Effects of metformin on glucagon-like peptide-1 levels examined - Obesity and Diabetes
Factors predicting metabolic syndrome and type 2 diabetes presented - Obesity and Diabetes
Preproghrelin gene not linked to obesity and type 2 diabetes - Adipose Tissue
Changes in fat mass influence SREBP-1c and UCP-2 gene expression - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
